Merck granted FDA approval for Keytruda as adjuvant therapy in renal cell carcinoma
November 18 2021 - 7:03AM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024